TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Eisai Co., Ltd. And Biogen Inc.
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

Eisai and Biogen announced that China's NMPA has accepted their Biologics License Application for a subcutaneous autoinjector formulation of LEQEMBI (lecanemab), an anti-amyloid beta antibody for early Alzheimer's disease treatment. If approved, this would be the first anti-amyloid treatment in China offering at-home injection from treatment initiation, potentially reducing healthcare resource requirements compared to intravenous administration.

Insights
BIIB   positive

Co-commercialization and co-promotion of lecanemab in China represents significant revenue opportunity. Regulatory progress in major market supports pipeline value and commercial potential, though Eisai holds final decision-making authority.